Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial

Use of sodium–glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study

(2020) Carina Iskander et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

(2020) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies

(2019) Jie Liu et al.   Diabetes & Vascular Disease Research

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging

(2019) Kengo Kidokoro et al.   CIRCULATION

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

(2019) Brendon L Neuen et al.   Lancet Diabetes & Endocrinology

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

(2019) Erik J.M. van Bommel et al.   KIDNEY INTERNATIONAL

11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020

(2019)   DIABETES CARE

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes

(2018) Petter Bjornstad et al.   DIABETES CARE

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

(2018) David Z.I. Cherney et al.   KIDNEY INTERNATIONAL

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV)

(2018) Christopher P. Cannon et al.   AMERICAN HEART JOURNAL

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

(2018) Thomas A Zelniker et al.   LANCET

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus

(2017) V. Sahasrabudhe et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial

(2017) David Z I Cherney et al.   Lancet Diabetes & Endocrinology

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

(2017) George Grunberger et al.   Diabetes Therapy

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

(2017) George Grunberger et al.   Diabetes Therapy

The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes

(2016) David Cherney et al.   DIABETOLOGIA

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

(2016) Paola Fioretto et al.   DIABETOLOGIA

Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition

(2016) Volker Vallon et al.   DIABETOLOGIA

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration

(2014) Andrew S. Levey et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

(2014) Marko Škrtić et al.   DIABETOLOGIA

Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality

(2014) Josef Coresh et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

(2014) Anthony H Barnett et al.   Lancet Diabetes & Endocrinology

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

(2013) David Z.I. Cherney et al.   CIRCULATION

Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials

(2011) H.J. Lambers Heerspink et al.   NEPHRON CLINICAL PRACTICE